Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 12/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.64 |
| ▸ | PGR | P06401 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL6 | P05231 | 1/20 | 0.64 |
| ▸ | GLUL | P15104 | 1/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781029 | 0.95 | HIF1A (0.66) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL945988 | 0.94 | HIF1A (0.65) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL11068491 | 0.93 | HIF1A (0.62) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL264554 | 0.93 | HIF1A (0.64) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL677626 | 0.93 | HIF1A (0.61) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL2326922 | 0.92 | HIF1A (0.63) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL28480766 | 0.92 | HIF1A (0.67) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL5955148 | 0.92 | HIF1A (0.62) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL3285984 | 0.91 | HIF1A (0.66) | HIF1ANR3C1HSD17B10PGRCYP3A4 | |
| SCHEMBL5484066 | 0.91 | HIF1A (0.60) | HIF1ANR3C1HSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117599290-A | Pressurized metered dose inhaler comprising buffered pharmaceutical formulation | 奇斯药制品公司 | 2024-02-27 | — | — | CN | claimed |
| CN-116098866-A | Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-12 | — | — | CN | claimed |
| CN-109963818-B | Method for air-quenching an elongated hollow glass body comprising an axial hole | 克鲁斯杰克特公司 | 2022-06-03 | — | — | CN | claimed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | claimed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | claimed |
| WO-2014178065-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-11-06 | — | — | WO | claimed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3622820-B1 | STABLE HYALURONAN/STEROID FORMULATION | GENZYME CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-4088756-A | TREATING PSORIASIS, DERMATITIS WITH ADRENERGIC AGENTS AND HYPOGLYCEMIC AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1978-05-09 | — | — | US | disclosed |
| US-4034087-A | TREATING PROLIFERATIVE SKIN DISEASES WITH 4-BENZYL-2-IMIDAZOLIDONES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1977-07-05 | — | — | US | disclosed |
| US-4018927-A | Treatment of proliferating skin diseases with papaverine alkaloids | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1977-04-19 | — | — | US | disclosed |
| US-4009282-A | Treatment of proliferating skin diseases with prostaglandins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1977-02-22 | — | — | US | disclosed |
| US-4007268-A | Process for alleviating proliferative skin diseases | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1977-02-08 | — | — | US | disclosed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | HIF1A 3779/4885NR3C1 614/4885HSD17B10 2421/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | HIF1A 3761/4885NR3C1 2701/4885HSD17B10 3792/4885 |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | HIF1A 3779/4885NR3C1 614/4885HSD17B10 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.